Description
Thromboxane A2 (TXA2) is a potent vasoconstrictor and activator of platelet aggregation. The short half-life of TXA2 ensures local action whether generated by vascular endothelial cells or by platelets and confers physiologically beneficial or deleterious effects under inflammatory situations.{146,11131} TXA2 elicits its effects via a 7-transmembrane domain G protein-coupled receptor, the TP receptor.{6062} This receptor can also bind prostaglandin H2 and isoprostanes and was first cloned from human placenta and the platelet-like MEG-01 cell line.{11146,7729} The TP receptor is highly expressed in platelets and is relatively less abundant in tissues such as lung, kidney, brain, spleen, thymus, monocytes, uterus, and placenta.{3167,11368,2061,4311,8380,7235}
Synonyms: Thromboxane A2 Receptor|TXA2 Receptor
Immunogen: Synthetic peptide from the C-terminal region of human TP receptor
Formulation: 500 µl of fluorescein-labeled, peptide affinity-purified antibody
Isotype:
Applications: FC
Origin: Animal/Rabbit
Stability: 365 days
Application|Flow Cytometry||Product Type|Antibodies|Polyclonal Antibodies||Research Area|Cardiovascular System|Blood||Research Area|Immunology & Inflammation|Innate Immunity||Research Area|Lipid Biochemistry|Cyclooxygenase Pathway
